JPMorgan to wager on weight-loss drug boom with $500M fund
JPMorgan Chase's asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs. The fu…
JPMorgan Chase's asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs. The fu…